The cryptocurrency-backed peptide market has surpassed the $100 million annual run rate after first-quarter sales jumped 159% quarter-on-quarter to $32 million, according to a new report by Chainalysis.
Summary
- Chainalysis says that the crypto-funded peptide market has exceeded the annual run rate of $100 million.
- Peptide sales for Q1 2026 jumped 159% quarter over quarter to $32 million.
- Average spend on independent purity testing has dropped by 88% per consumer, raising safety concerns as demand for peptides continues to grow.
According to Chainalysis, demand for off-label peptides has grown rapidly beyond niche biohacking communities, creating a gray market industry that relies heavily on cryptocurrency payments.
The blockchain analytics firm said peptide sales reached $32 million in the first quarter of 2026, up from $12 million in the previous quarter.
Peptides, which are short chains of amino acids used in health, fitness, and wellness products, have gained attention following the success of GLP-1 drugs such as Ozempic and Wegovy. Chainalysis said that growing consumer interest in weight loss, performance enhancement, and recovery products has pushed many consumers to alternative peptide suppliers that operate outside of traditional pharmaceutical channels.
Many of those providers are based in China, where access to traditional banking services can be limited to businesses that sell pharmaceutical-grade compounds and controlled substances. As a result, Chainalysis said that cryptocurrency has become the main payment train that connects international producers and consumers.
Stablecoins have become a popular payment method
Examining the on-chain activity linked to major peptide vendors, Chainalysis found that major providers are increasingly favoring stablecoins over volatile cryptocurrencies.
The company said merchants who receive average deposits of at least $1,000 show a payment mix controlled by stablecoins, suggesting an effort to reduce exposure to crypto price fluctuations while handling large supply chain transactions.
What started as a small market catering to niche consumers has evolved into a more organized ecosystem, according to Chainalysis.
The report noted that leading merchants are adopting increasingly complex financial processes while continuing to process significant amounts through Bitcoin and stablecoins.
Chainalysis compared peptide trading to other gray market industries that have historically turned to cryptocurrency after encountering restrictions from banks and payment processors. The company said suppliers can offer raw and unbranded products directly to consumers at prices far below those available through regulated channels.
The findings also fit with broader trends previously identified by Chainalysis. Earlier this year, the company reported that cryptocurrency flows to suspected smuggling services would increase by 85% by 2025, with stablecoin-heavy networks operating through Telegram and other online platforms.
Chainalysis said the blockchain’s transparency, however, provides investigators with permanent transaction records that can help track financial activity and identify key intermediaries.
The use of quality testing has decreased despite the increase in demand
Along with rising sales, Chainalysis has identified a decrease in spending on independent product testing among peptide consumers.
The company said many customers previously sent payments to peptide suppliers and to Janoshik, a Czech laboratory that tests chemical purity. As the number of consumers increased, however, the cost of testing failed to keep pace with sales growth.
According to Chainalysis estimates, spending on testing per consumer has dropped 88% to about $8, even though Janoshik is conducting more tests than ever. The decline occurred because new demand entered the market faster than increased testing activity.
Security concerns have also been raised about some providers involved in the industry. Chainalysis reported that Shanghai Sigma Audley, a company linked to organizations previously involved in the sale of fentanyl precursors, generated at least $ 1 million in Bitcoin and $ 3.59 million in stablecoins before expanding into the sale of the peptide.
Given the combination of unregulated products and cryptocurrency-based transactions, Chainalysis warned that many new customers entering the sector may have limited knowledge of any market, increasing potential risks as the industry continues to grow.
